The Possible Role of the Incretin Enhancer Sitaglipten, in Renal Ischemic Reperfusion Injury in Type 2 Diabetes Mellitus ()
ABSTRACT
Background:
Diabetes mellitus (DM) especially type 2 is a major health problem and diabetic
nephropathy is the main cause of end stage renal disease (ESRD).
Renal ischemia/reperfusion (I/R) injury is common in diabetic patients. Recent
studies reported increased vulnerability of kidneys to I/R injury in diabetic rats.
In view of the reported efficacy of incretin enhancer on I/R injury. Aim: This
study was designed to assess the effect of sitaglipten on renal I/R in type 2
diabetes mellitus . Methods: Type 2 DM in rats were induced by administration
of nicotinamide (230 mg/kg, i.p.), 15 min prior to the single dose of
streptozotocin (65 mg/kg, i.p.). Renal
I/R were performed in both diabetic and normal rats. Results: The lipid
peroxidation, xanthine oxidase activity, and nitric oxide levels were
significantly increased after I/R in diabetic rats compared to I/R in normal
rats. Antioxidant enzymes such as glutathione, superoxide dismutase, catalase,
and glutathione peroxidase were significantly reduced after I/R in diabetic
rats compared to normal rats. Sitaglipten treatment significantly normalized
these biochemical parameters compared to diabetic I/R rats. Serum TNF-α level and myeloperoxidase activity
were also significantly normalized after administration of sitaglipten.
Furthermore, treatment with sitaglipten (10 mcg/kg) had preserved the normal
morphology of the kidney compared to I/R performed in diabetic rats. Conclusion:
Sitaglipten protects exaggerated renal I/R injury in type 2 DM. These findings
have major implication in the treatment of ischemic injury that is prone to
develop in DM.
Share and Cite:
Mohamed, M. , Hammadi, S. and Hamid, M. (2014) The Possible Role of the Incretin Enhancer Sitaglipten, in Renal Ischemic Reperfusion Injury in Type 2 Diabetes Mellitus.
Open Journal of Endocrine and Metabolic Diseases,
4, 181-196. doi:
10.4236/ojemd.2014.47018.